UCB, a biopharmaceutical company, will present results from Phase 3 studies investigating the impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa at the Symposium on Hidradenitis Suppurativa Advances. The data provide further evidence of bimekizumab’s potential to treat this chronic inflammatory condition. Despite promising results, the drug has not yet been approved by the US Food and Drug Administration.
ISC Stormcast For Monday, September 15th, 2025 https://isc.sans.edu/podcastdetail/9612
ISC Stormcast For Monday, September 15th, 2025 (Mon, Sep 15th)
